Cyclooxygenase 2 controversy: thoughts on the process of discovery, development, and assessment of benefit and risk of therapies for chronic immunoinflammatory diseases of uncertain autoimmune etiology.
Furst
Daniel E
DE
Khanna
Dinesh
D
Paulus
Harold E
HE
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D015551:Autoimmunity / Q000502:physiology; D002908:Chronic Disease; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D017277:Drug Approval; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D018570:Risk Assessment
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors